Demographics and baseline characteristics were similar between treatment groups (Table 1). Before study entry, in addition to insulin,most patients were treated with either metformin alone (51.6%) ormetformin and a sulphonylurea (31.0%), with the remainder receivinga sulphonylurea alone (3.9%) or no additional glucose-lowering ther- apy (13.4%) (Table 1). Treatment compliance was high across groups, with 92.7% and 93.9% of exenatide QW-treated patients and placebo-treatedpatients, respectively, using 80% to <120% of the dispensed studymedication. 3.2 |Efficacy 3.2.1 |Glycaemic control At screening, mean HbA1c, FPG and daily IG dose were similar